# 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

> **NCT00345696** · PHASE2 · COMPLETED · sponsor: **Unidad Integral de Investigación en Oncología S.L.** · enrollment: 32 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatine

## Key facts

- **NCT ID:** NCT00345696
- **Lead sponsor:** Unidad Integral de Investigación en Oncología S.L.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-10
- **Final completion:** 2011-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2011-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345696, "1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00345696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*